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Repeated disinfection of a nebulizer may modify its performance. During 60 cycles of disinfection with the Nuk® steam sterilizer (120
nebulizations), the median volume diameter of tobramycin or colistin, nebulization time and various parameters correlated with the
membrane weight of the e-Flow rapid® are not modified. Results are similar when tap or purified water is used for washing and disinfection.
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Repeated washing and disinfection of a nebulizer to guard
against possible microbiological contamination with cystic
fibrosis patients [1,2] may modify its performance [3]. With
the new mesh nebulizer e-Flow rapid® (Pari GmbH,
München, Germany), risk of obstruction of the multiple
holes of the membrane by repeated use of drugs and/or
disinfecting agents is usually evaluated by checking
nebulization time once per month. This in vitro study
examines possible modifications of the e-Flow rapid®
performance when it is used with antibiotics (tobramycin
or colistin) and disinfected with the recommended Nuk®
steam sterilizer (Mapa GmbH, Zeven, Germany). As
numerous patients, in practice, use purified water in the
Nuk® to avoid potential sediments on the membrane due to
hard water, we also compare how tap or purified water used
during washing and disinfection may affect the membrane.⁎ Corresponding author. Unité de Médecine Infantile, CHU Timone-
Enfants, 13385 Marseille Cedex 5, France. Tel.: +33 491386739; fax: +33
491385638.
E-mail address: jean-christophe.dubus@ap-hm.fr (J.-C. Dubus).
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The e-Flow rapid® was used as follows: (1) one
nebulization with tobramycin (Tobi®, 300 mg/5 ml, Chiron
Laboratories) or colistin (Colimycine®, prepared 5 min
before use, 2,000,000 IU/6 ml, Aventis Laboratories); (2)
nebulizer washed with liquid soap water for dishes (20%
ionic and 5% non ionic surfactant), rinsed with clear water,
and dried in ambient air; (3) a second nebulization with the
same drug; (4) nebulizer washed and disinfected using the
Nuk® for 15 min; (5) repetition of these four steps up to a
total of 120 nebulizations. Three different groups were
studied: one with tobramycin and another with colistin, both
using tap water for all steps of washing, rinsing and
disinfection; a third group, with tobramycin, used only
purified water throughout the procedure.
For each group, we carried out 2 successive nebulizations
measuring at baseline, after 30, 45 and 60 disinfection
procedures: (1) median volume diameter (MVD, in μm) with
a Malvern laser diffraction; (2) nebulization time (in min)
with a chronometer, stopped when a beep indicated the end
of the nebulization; (3) several parameters linked to the
weight of the membrane by gravimetric method with aned by Elsevier B.V. All rights reserved.
Table 1
Values (mean±standard deviation) of parameters obtained when nebulizing
tobramycin and colistin with an e-Flow rapid®, disinfected with a Nuk®
steam sterilizer, at baseline and after 30, 45, and 60 cycles of disinfection
(n=4 measurements per value)
Tobramycin Colistin
Tap water Purified water Tap water
Median volume diameter (μm)
– at baseline 5.25±0.24 5.29±0.18 5.09±0.2
– after 30 cycles 5.00±0.30 5.23±0.24 5.00±0.14
– after 45 cycles 5.14±0.16 5.17±0.24 5.09±0.24
– after 60 cycles 5.27±0.13 5.27±0.26 5.09±0.18
Nebulization time (min)
– at baseline 6.02±0.81 6.25±0.45 4.04±0.22
– after 30 cycles 5.52±0.57 5.57±0.57 4.48±0.57
– after 45 cycles 5.75±0.53 6.02±0.61 4.10±0.81
– after 60 cycles 6.25±0.49 6.72±0.58 4.51±0.58
Membrane weight before use (g)
– at baseline 7.1469±0.026 7.1475±0.012 7.1692±0.006
– after 30 cycles 7.1569±0.027 7.1697±0.006 7.1780±0.005
– after 45 cycles 7.1562±0.025 7.1657±0.011 7.1827±0.005
– after 60 cycles 7.1602±0.027 7.1644±0.011 7.1831±0.005
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10 μg: weight before use (in g), difference in weight before
and after each nebulization (in mg), increase in weight after
30, 45 and 60 cycles from baseline (in mg). Using 2 different
brand-new e-Flow rapid® per group, a total of 4 measure-
ments per parameter per group was obtained for each period
of treatment. All the nebulizations were performed with
active drugs under an extractor hood.
Results were expressed as mean and standard deviation.
We did not perform statistical tests because only 2 devices
were tested, with an impossibility to describe the inter-device
variability.
3. Results
The principal results are shown in Table 1.
When tap water was used for washing and disinfection,
the median volume diameter and the nebulization time did
not at any time during the experiment differ for tobramycin
nebulization. The use of purified water did not alter the
performance of the nebulizer used with tobramycin.
Whatever the type of water used, the membrane weight
difference before and after each nebulization was very low,
ranging from −2.17±1.41 mg to 0.47±2.58 mg. The
increase in weight from baseline with tobramycin was
maximum 17 mg (i.e. less than 0.02% weight increase).
With colistin, there was a shorter nebulization time and a
higher membrane weight than with tobramycin. MVD and
nebulization time did not differ during the study period. The
various parameters linked to the membrane weight were
similar up to 60 cycles (difference in weight before and after
use ranging from −0.05±0.44 mg to 0.40±0.94 mg; increasein weight from baseline of about 12 mg, despite eye-visible
sediments seen on the membrane).
4. Discussion
Because of the wide range of nebulizers available and the
diversity of cleaning methods used in home practice [4],
more in vitro studies need to be conducted by independent
laboratories before nebulizer cleaning methods can properly
be assessed, both in terms of microbiological efficacy and of
effects on the aerosol. Ideally, such studies should be based
on a similar standardized methodology (type and quantity of
microorganisms to be eradicated, nebulizer parameters to be
measured, drug to be used, number of experiments to be
repeated and nebulizers to be tested).
Although our study only focuses on the in vitro
membrane performance of the e-Flow rapid®, our results
address a major question concerning its use with different
antibiotics and its washing and disinfection with Nuk® using
tap or purified water. No alteration of the membrane is
observed with the steam sterilization procedure up to 60
cycles (=2 months of treatment), whatever the antibiotic or
the type of water used. Of course, our study was limited to
only 120 nebulizations, and drug output from the nebulizer
was not directly evaluated. However, the various parameters
linked to the weight of the membrane indirectly reflect the
output rate. Despite the absence of microscopic evaluation to
differentiate a problem of surface deposition or hole
obstruction, they seem to indicate that the inhaled antibiotics
used during the study period do not modify the membrane
function.
Based on our results, we have no objective argument for
recommending a more expensive procedure than tap water
use with Nuk® to wash and disinfect the e-Flow rapid®.
Thanks
Thanks to the “Aerosol Group” of the French Cystic
Fibrosis Society for stimulating discussions on this subject.
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